- Home
- NRSN vs ANTX Comparison
NRSN vs ANTX Comparison
Compare NRSN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- ANTX
- Stock Information
- Founded
- NRSN 2017
- ANTX 2017
- Country
- NRSN Israel
- ANTX United States
- Employees
- NRSN N/A
- ANTX N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- ANTX Health Care
- Exchange
- NRSN Nasdaq
- ANTX Nasdaq
- Market Cap
- NRSN 29.8M
- ANTX 34.4M
- IPO Year
- NRSN 2021
- ANTX 2022
- Fundamental
- Price
- NRSN $1.18
- ANTX $1.19
- Analyst Decision
- NRSN Buy
- ANTX Buy
- Analyst Count
- NRSN 2
- ANTX 2
- Target Price
- NRSN $14.00
- ANTX $2.00
- AVG Volume (30 Days)
- NRSN 243.1K
- ANTX 52.7K
- Earning Date
- NRSN 11-03-2025
- ANTX 11-12-2025
- Dividend Yield
- NRSN N/A
- ANTX N/A
- EPS Growth
- NRSN N/A
- ANTX N/A
- EPS
- NRSN N/A
- ANTX N/A
- Revenue
- NRSN N/A
- ANTX N/A
- Revenue This Year
- NRSN N/A
- ANTX N/A
- Revenue Next Year
- NRSN N/A
- ANTX N/A
- P/E Ratio
- NRSN N/A
- ANTX N/A
- Revenue Growth
- NRSN N/A
- ANTX N/A
- 52 Week Low
- NRSN $0.80
- ANTX $0.98
- 52 Week High
- NRSN $2.60
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- NRSN 44.09
- ANTX 42.94
- Support Level
- NRSN $1.15
- ANTX $1.13
- Resistance Level
- NRSN $1.30
- ANTX $1.25
- Average True Range (ATR)
- NRSN 0.07
- ANTX 0.06
- MACD
- NRSN -0.00
- ANTX -0.01
- Stochastic Oscillator
- NRSN 31.43
- ANTX 22.73
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.